Welcome and thank you for visiting the MC2 Biotek Group website

MC2 Biotek is a privately held emerging specialty pharma company applying its proprietary PAD™ technology - a new class of cream and eye droplet - to develop a pipeline of new topical drugs and medical devices that addresses the major problem of non-compliance of otherwise highly efficacious and safe topical therapies (dermatology and ophthalmology). 


Our patient-focused approach will provide PAD™ based topical therapies that patients will want to use (rather than have to use) because they are very elegant and pleasant to use on the skin and in the eyes without compromising best-in-class efficacy and safety. Patients will feel free to engage with other people and be as active and social as they want during treatment. Clinical benefits to patients and cost efficient treatment for payers.


MC2 Biotek is domiciled in Copenhagen, Denmark (Headquarter) and in Leatherhead southwest of London, UK (Formulation).


Other activities in the MC2 Biotek Group include development of a small molecule (RX-1) for type 2 diabetes and a novel 3D Tissue Culture system. Such activities are run in separate legal entities independent of the activities in dermatology and ophthalmology.

Latest news
MC2 Biotek to present at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in May
Read more
Meet MC2 Biotek at EADV in Copenhagen
Read more
MC2 Biotek Group

Agern Allé 24-26

DK-2970 Hørsholm

Tel: +45 2018 1111

Fax: +45 7021 5216